Men's Health News

RSS

Advanced Medical Diagnostics SA to open 15 Tissue Differentiation Diagnostic Centres

Advanced Medical Diagnostics SA, a privately held company committed to providing innovative computer-aided solutions (HistoScanning™) that improve the diagnostic interpretation of ultrasound scans, today announced a collaboration with the BUND-DER-UROLOGEN for the opening of 15 Tissue Differentiation Diagnostic Centres.

18 Dec 2009

Link between ill-health and retirement age varies across European countries

A study of the impact of health "shocks" on the decision of individuals to retire early found that for men, rapidly deteriorating health had the largest impact in Ireland, Portugal, Greece and Spain.

18 Dec 2009

Shift working may accelerate metabolic syndrome

Shift work exposures can accelerate metabolic syndrome (MetS) development among the large population of middle-aged males with elevated alanine aminotransferase (ALT). Elevated serum alanine aminotransferase (e-ALT) is a common abnormality of health examinations in middle-aged working populations.

17 Dec 2009

New offers on penis extender device during holiday season

Just in time for the holidays, Quick Extender Pro™, an industry leader in penis enlargement, is offering 25% off their penis extender device along with a free bonus holiday gift.

17 Dec 2009

Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced top-line efficacy and safety results from a Phase 2b clinical trial of XIAFLEX(TM) for the treatment of Peyronie's disease.

17 Dec 2009

Makefield Therapeutics to patent applications covering its Hybrid Nanoparticle drug delivery platform

Makefield Therapeutics, Inc., an emerging therapeutics company, today announced that it has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield's biodegradable Hybrid Nanoparticles™, a versatile new drug delivery platform.

16 Dec 2009

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced top-line efficacy and safety results for the phase IIb clinical trial for XIAFLEX™ (collagenase clostridium histolyticum) in the treatment of Peyronie's disease.

16 Dec 2009

Prostate cancer tests promised but not delivered

Men's Health Network calls on Congress to ensure that healthcare reform does not override the prostate cancer testing benefit currently required of insurance companies in 37 states.

16 Dec 2009

Teens, contraception and unplanned pregnancy

Nearly all unmarried young adults ages 18-29 believe pregnancy is something that should be planned (94% of men and 86% of women) and say that it is important to avoid pregnancy in their lives right now (86% of men and 88% of women), according to new research released by The National Campaign to Prevent Teen and Unplanned Pregnancy.

15 Dec 2009

Preventing tumours from making new blood vessels can also prevent spread of cancer

Patients with advanced prostate cancer are often treated with hormones, but when the tumours start growing again they have more and different blood vessels, reveals a thesis from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. This discovery paves the way for new treatments for hormone-resistant prostate cancer.

15 Dec 2009

Pure populations of immature cells that enable male reproduction isolated and transplanted

Reproductive researchers from the University of Pennsylvania and The Children's Hospital of Philadelphia have succeeded in isolating and transplanting pure populations of the immature cells that enable male reproduction in two species-human spermatogonia and mouse gonocytes. These germline stem cells, taken from testis biopsies, demonstrated viability following transplantation to mouse testes within a controlled laboratory setting.

15 Dec 2009

Increased physical activity decreases risk of colorectal cancer

Increased physical activity appears to be associated with a lower risk of cancer-specific and overall death in men with a history of colorectal cancer that has not spread to other parts of the body, according to a report in the December 14/28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 Dec 2009

New program to help maintain bone health in men with prostate cancer on ADT announced

Watson Pharmaceuticals, Inc. today announced a new program encouraging health professionals to help maintain the bone health of prostate cancer patients who are on long-term androgen deprivation therapy (ADT).

15 Dec 2009

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Algeta ASA, the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton.

14 Dec 2009

Researchers discover new explanation for differences in severity of mental illness in males

Researchers have discovered a new explanation for differences in the severity of mental illness in males. The more excess copies of a certain gene, the more serious the handicap. The genetic defect is situated on the X-chromosome; and it is suspected that it is the amount of copies of the GDI1 gene that is responsible.

11 Dec 2009

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

Watson Pharmaceuticals, Inc. today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment. RAPAFLO® is an effective and uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), the number one reason patients visit urologists.

9 Dec 2009

Also in Global Health news: Rotavirus vaccine; guinea worm eradication; health systems; Zulu King calls for male circumcision

The West African Rotavirus Advisory Board is calling on governments to vaccinate children against rotavirus, IRIN reports. At a recent meeting in Dakar, Senegal, which was "financed by GlaxoSmithKline, makers of one of two rotavirus vaccines" the board issued a document recommending that governments "immediately recognize the magnitude of the rotavirus problem and make vaccination against the virus a priority" (12/8).

8 Dec 2009

Exercise can reduce overall mortality rates in patients with prostate cancer, according to findings

As little as 15 minutes of exercise a day can reduce overall mortality rates in patients with prostate cancer, according to findings presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held here, Dec. 6-9, 2009.

8 Dec 2009

Data shows strong inverse association between coffee consumption and advanced prostate cancer

While it is too early for physicians to start advising their male patients to take up the habit of regular coffee drinking, data presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference revealed a strong inverse association between coffee consumption and the risk of lethal and advanced prostate cancers.

8 Dec 2009

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

7 Dec 2009

Men's Health News

Advanced Medical Diagnostics SA to open 15 Tissue Differentiation Diagnostic Centres

Link between ill-health and retirement age varies across European countries

Shift working may accelerate metabolic syndrome

New offers on penis extender device during holiday season

Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced

Makefield Therapeutics to patent applications covering its Hybrid Nanoparticle drug delivery platform

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Prostate cancer tests promised but not delivered

Teens, contraception and unplanned pregnancy

Preventing tumours from making new blood vessels can also prevent spread of cancer

Pure populations of immature cells that enable male reproduction isolated and transplanted

Increased physical activity decreases risk of colorectal cancer

New program to help maintain bone health in men with prostate cancer on ADT announced

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Researchers discover new explanation for differences in severity of mental illness in males

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

Also in Global Health news: Rotavirus vaccine; guinea worm eradication; health systems; Zulu King calls for male circumcision

Exercise can reduce overall mortality rates in patients with prostate cancer, according to findings

Data shows strong inverse association between coffee consumption and advanced prostate cancer

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News